September 13, 2021
As per the research literature titled ‘Asia Pacific Animal Model Market Forecast 2027 By End-use, By Animal Type, By Technology, By Application, By Use, Research Report, Regional Outlook, COVID-19 Impact Statistics, Price Trends, Historic Data, Growth Prospects, Competitive Industry Share’, available with Market Study Report, Asia Pacific animal model market is projected to surpass a valuation of USD 6.5 billion by the end of the forecast period 2021-2027.
As per the report findings, Asia Pacific animal model market is mainly driven by increasing pharmaceutical R&D activities, rising demand for personalized medications among patients suffering from various ailments, and emergence of advanced technologies like CRISPR.
Request sample copy of this Report: https://www.marketstudyreport.com/request-a-sample/4037661/
Notably, animal models have been leveraged for various scientific discoveries for several decades and have become an integral part of many groundbreaking researches in the field of disease treatment. Physiological similarities between human and animal, along with the wide array of applications in healthcare sector will continue to stimulate the demand for animal models in the upcoming years.
Based on animal type, rats, mice, fish, birds, pigs, guinea pigs, cattle, amphibians, cats, dogs, monkeys, rabbits, hamsters, and sheep are the key segments highlighted in the Asia Pacific animal model market report.
Expert analysts cite that monkeys segment is anticipated holds considerable industry share in the upcoming years. This can be ascribed to the identical genomic structure, reproduction capabilities, and physiology of monkeys to that of human that has favored the use of this animal model among researchers to study neurological diseases like Parkinson’s and Alzheimer’s, and autoimmune diseases like AIDS.
On the geographical front, China is anticipated to contribute substantially to the progress of animal model market in Asia Pacific as it has an abundance of animal colonies. Moreover, supportive government policies and schemes to encourage researchers to discover medical breakthrough in terms of new medicines and other scientific procedures are augmenting the industry growth in China.
Prominent industry players in the APAC region are GVKB Biosciences (Aragen Life Sciences Pvt. Ltd.), Ozgene Pty Ltd., Crown Bioscience Inc., Taconic Biosciences Inc., TransGenic Inc., PharmaLegacy Laboratories, Harbour BioMed, Cyagen Biosciences, GenOway, Envigo, and Charles River Laboratories.